Livzon Pharma Unit Wins China Approval for Fertility Drug Biosimilar
Livzon Pharmaceutical's (HKG:1513, SHE:000513) unit Livzon MABPharm received approval from China's National Medical Products Administration for Recombinant Human Follitropin Alfa Solution for Injection, according to a Monday Hong Kong bourse filing.The product is indicated for anovulation, including polycystic ovary syndrome, ovarian stimulation in assisted reproductive technology procedures, and certain patients with severe luteinizing hormone and follicle-stimulating hormone deficiencies.The drug is administered through a pre-filled injection pen and was developed as a biosimilar.